January 26th 2021, 8:09pm
Periodic review of treatment safety and monitoring are necessary as medical centers increasingly use newer disease-modifying therapies earlier in the course of multiple sclerosis.
December 27th 2020, 1:00pm
The coronavirus disease 2019 (COVID-19) pandemic dominated headlines for much of 2020, and most of the top 5 multiple sclerosis articles of this year discussed the effects of COVID-19 on patients with this disease. Others touched on physician and patient assessments of relapse and potential new treatments for neural damage.
December 23rd 2020, 8:51pm
Researchers analyzed the available evidence on the treatment’s efficacy and safety profile from the RADIANCE and SUNBEAM trials.
December 19th 2020, 7:30pm
As a neurodegenerative disease, secondary progressive multiple sclerosis (SPMS) may lead to a degradation of cognition skills as the disease progresses.
December 16th 2020, 11:30pm
A new study indicates that an analysis of serum and cerebrospinal fluid cytokine levels can identify multiple sclerosis and its forms.
December 12th 2020, 11:45pm
The German multiple sclerosis (MS) study found differences by gender for some costs, but the overall economic burden of the disease was about the same.
December 12th 2020, 8:00pm
A recent review examines the prevalence of headache among patients with multiple sclerosis, particularly migraine.
December 5th 2020, 6:15pm
The Dutch study sought to add to what is known about the cost-effectiveness of shared decision-making in multiple sclerosis.
November 29th 2020, 12:45pm
Multiple factors come into play when providers and patients discuss a disease-modifying therapy for multiple sclerosis (MS), explains Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute.
November 25th 2020, 9:00pm
Prior research has found increased colon and breast cancer in patients with multiple sclerosis (MS), but that was not borne out in this current study.
